"Designing Growth Strategies is in our DNA"

HIV Drugs Market Size, Share & COVID-19 Impact Analysis, By Drug Class (Integrase Inhibitors, Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Combination HIV Medicines, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others), and Regional Forecast, 2021-2028

Region : Global | Format: PDF | Report ID: FBI101115

 

  1. Introduction
    1. Research Scope
    2. Market Segmentation
    3. Research Methodology
    4. Definitions and Assumptions
  2. Executive Summary
  3. Market Dynamics
    1. Market Drivers
    2. Market Restraints
    3. Market Opportunities
  4. Key Insights
    1. Epidemiology of HIV/AIDS, By Key Countries/Regions, 2020
    2. Regulatory Scenario by Key Countries
    3. Pipeline Analysis
    4. Overview of Current Advances in R&D for HIV Drugs
    5. Key Strategies Employed by Market Leaders
    6. Key Industry Developments
    7. New Product Launches
  5. Global HIV Drugs Market Analysis, Insights and Forecast, 2017-2028
    1. Key Findings / Summary
    2. Market Analysis, Insights and Forecast – By Drug Class
      1. Integrase Inhibitors  
      2. Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
      3. Combination HIV Medicines
      4. Others
    3. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
      4. Others
    4. Market Analysis, Insights and Forecast – By Region
      1. North America
      2. Europe
      3. Asia Pacific
      4. Rest of the World
  6. North America HIV Drugs Market Analysis, Insights and Forecast, 2017-2028
    1. Key Findings / Summary
    2. Market Analysis – By Drug Class
      1. Integrase Inhibitors  
      2. Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
      3. Combination HIV Medicines
      4. Others
    3. Market Analysis – By Distribution Channel
      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
      4. Others
    4. Market Analysis – By Country
      1. U.S.
        1. By Drug Class
          1. Integrase Inhibitors  
          2. Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
          3. Combination HIV Medicines
          4. Others
      2. Canada
        1. By Drug Class
          1. Integrase Inhibitors  
          2. Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
          3. Combination HIV Medicines
          4. Others
  7. Europe HIV Drugs Market Analysis, Insights and Forecast, 2017-2028
    1. Key Findings / Summary
    2. Market Analysis – By Drug Class
      1. Integrase Inhibitors  
      2. Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
      3. Combination HIV Medicines
      4. Others
    3. Market Analysis – By Distribution Channel
      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
      4. Others
    4. Market Analysis – By Country/ Sub-Region
      1. Germany
        1. By Drug Class
          1. Integrase Inhibitors  
          2. Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
          3. Combination HIV Medicines
          4. Others
      2. France
        1. By Drug Class
          1. Integrase Inhibitors  
          2. Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
          3. Combination HIV Medicines
          4. Others
      3. U.K.
        1. By Drug Class
          1. Integrase Inhibitors  
          2. Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
          3. Combination HIV Medicines
          4. Others
      4. Italy
        1. By Drug Class
          1. Integrase Inhibitors  
          2. Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
          3. Combination HIV Medicines
          4. Others
      5. Spain
        1. By Drug Class
          1. Integrase Inhibitors  
          2. Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
          3. Combination HIV Medicines
          4. Others
      6. Netherlands
        1. By Drug Class
          1. Integrase Inhibitors  
          2. Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
          3. Combination HIV Medicines
          4. Others
      7. Rest of Europe
        1. By Drug Class
          1. Integrase Inhibitors  
          2. Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
          3. Combination HIV Medicines
          4. Others
  8. Asia Pacific HIV Drugs Market Analysis, Insights and Forecast, 2017-2028
    1. Key Findings / Summary
    2. Market Analysis – By Drug Class
      1. Integrase Inhibitors  
      2. Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
      3. Combination HIV Medicines
      4. Others
    3. Market Analysis – By Distribution Channel
      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
      4. Others
    4. Market Analysis – By Country/ Sub-Region
      1. China
        1. By Drug Class
          1. Integrase Inhibitors  
          2. Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
          3. Combination HIV Medicines
          4. Others
      2. Japan
        1. By Drug Class
          1. Integrase Inhibitors  
          2. Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
          3. Combination HIV Medicines
          4. Others
      3. India
        1. By Drug Class
          1. Integrase Inhibitors  
          2. Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
          3. Combination HIV Medicines
          4. Others
      4. Australia
        1. By Drug Class
          1. Integrase Inhibitors  
          2. Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
          3. Combination HIV Medicines
          4. Others
      5. South Korea
        1. By Drug Class
          1. Integrase Inhibitors  
          2. Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
          3. Combination HIV Medicines
          4. Others
      6. Rest of Asia Pacific
        1. By Drug Class
          1. Integrase Inhibitors  
          2. Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
          3. Combination HIV Medicines
          4. Others
  9. Rest of the World HIV Drugs Market Analysis, Insights and Forecast, 2017-2028
    1. Key Findings / Summary
    2. Market Analysis – By Drug Class
      1. Integrase Inhibitors  
      2. Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
      3. Combination HIV Medicines
      4. Others
    3. Market Analysis – By Distribution Channel
      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
      4. Others
  10. Competitive Analysis
    1. Global Market Share Analysis (2020)
    2. Company Profiles (Overview, Products & Services, SWOT Analysis, Recent Developments, Strategies, Financials (Based On Availability))
      1. ViiV Healthcare
        1. Overview,
        2. Products & Services,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. Financials (Based On Availability)
      2. Gilead Sciences, Inc.
        1. Overview,
        2. Products & Services,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. Financials (Based On Availability)
      3. GlaxoSmithKline plc
        1. Overview,
        2. Products & Services,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. Financials (Based On Availability)
      4. Merck Sharp & Dohme Corp.
        1. Overview,
        2. Products & Services,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. Financials (Based On Availability)
      5. Bristol-Myers Squibb Company
        1. Overview,
        2. Products & Services,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. Financials (Based On Availability)
      6. Janssen Pharmaceuticals, Inc.
        1. Overview,
        2. Products & Services,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. Financials (Based On Availability)
      7. Boehringer Ingelheim International GmbH
        1. Overview,
        2. Products & Services,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. Financials (Based On Availability)
      8. AbbVie Inc.
        1. Overview,
        2. Products & Services,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. Financials (Based On Availability)
      9. Genentech, Inc. (F. Hoffmann-La Roche AG)
        1. Overview,
        2. Products & Services,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. Financials (Based On Availability)
      10. Mylan N.V.
        1. Overview,
        2. Products & Services,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. Financials (Based On Availability)
Read Less

Figure 1:  Global HIV Drugs Market Revenue Breakdown (USD billion, %) by Region, 2020 & 2028

Figure 2:  Global HIV Drugs Market Value Share (%), by Drug Class, 2020 & 2028

Figure 3:  Global HIV Drugs Market Forecast (USD billion), by Integrase Inhibitors, 2017-2028

Figure 4:  Global HIV Drugs Market Forecast (USD billion), by Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs), 2017-2028

Figure 5:  Global HIV Drugs Market Forecast (USD billion), by Combination HIV Medicines, 2017-2028

Figure 6:  Global HIV Drugs Market Forecast (USD billion), by Others, 2017-2028

Figure 7:  Global HIV Drugs Market Value Share (%), by Distribution Channel, 2020 & 2028

Figure 8:  Global HIV Drugs Market Forecast (USD billion), by Hospital Pharmacies, 2017-2028

Figure 9:  Global HIV Drugs Market Forecast (USD billion), by Retail Pharmacies, 2017-2028

Figure 10:  Global HIV Drugs Market Forecast (USD billion), by Online Pharmacies, 2017-2028

Figure 11:  Global HIV Drugs Market Forecast (USD billion), by Others, 2017-2028

Figure 12:  Global HIV Drugs Market Value (USD billion), by Region, 2020 & 2028

Figure 13:  North America HIV Drugs Market Value (USD billion), by Drug Class, 2020 & 2028

Figure 14:  North America HIV Drugs Market Value Share (%), by Drug Class, 2020

Figure 15:  North America HIV Drugs Market Value (USD billion), by Distribution Channel, 2020 & 2028

Figure 16:  North America HIV Drugs Market Value Share (%), by Distribution Channel, 2020

Figure 17:  North America HIV Drugs Market Value (USD billion), By Country, 2020 & 2028

Figure 18:  North America HIV Drugs Market Value Share (%), By Country, 2020

Figure 19:  Europe HIV Drugs Market Value (USD billion), by Drug Class, 2020 & 2028

Figure 20:  Europe HIV Drugs Market Value Share (%), by Drug Class, 2020

Figure 21:  Europe HIV Drugs Market Value (USD billion), by Distribution Channel, 2020 & 2028

Figure 22:  Europe HIV Drugs Market Value Share (%), by Distribution Channel, 2020

Figure 23:  Europe HIV Drugs Market Value (USD billion), By Country/ Sub-region, 2020 & 2028

Figure 24:  Europe HIV Drugs Market Value Share (%), By Country/ Sub-region, 2020

Figure 25:  Asia Pacific HIV Drugs Market Value (USD billion), by Drug Class, 2020 & 2028

Figure 26:  Asia Pacific HIV Drugs Market Value Share (%), by Drug Class, 2020

Figure 27:  Asia Pacific HIV Drugs Market Value (USD billion), by Distribution Channel, 2020 & 2028

Figure 28:  Asia Pacific HIV Drugs Market Value Share (%), by Distribution Channel, 2020

Figure 29:  Asia Pacific HIV Drugs Market Value (USD billion), By Country/ Sub-region, 2020 & 2028

Figure 30:  Asia Pacific HIV Drugs Market Value Share (%), By Country/ Sub-region, 2020

Figure 31:  Rest of the World HIV Drugs Market Value (USD billion), by Drug Class, 2020 & 2028

Figure 32:  Rest of the World HIV Drugs Market Value Share (%), by Drug Class, 2020

Figure 33:  Rest of the World HIV Drugs Market Value (USD billion), by Distribution Channel, 2020 & 2028

Figure 34:  Rest of the World HIV Drugs Market Value Share (%), by Distribution Channel, 2020

Figure 35:  Global HIV Drugs Market Share (%), By Company, 2020

Table 1:  Global HIV Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2017–2028

Table 2:  Global HIV Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2017–2028

Table 3:  Global HIV Drugs Market Revenue (USD billion) Forecast, by Region, 2017-2028

Table 4:  North America HIV Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2017-2028

Table 5:  North America HIV Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2017-2028

Table 6:  North America HIV Drugs Market Revenue (USD billion) Forecast, By Country, 2017-2028

Table 7:  U.S. HIV Drugs Market Revenue (USD billion) Forecast, By Drug Class, 2017–2028

Table 8:  Canada HIV Drugs Market Revenue (USD billion) Forecast, By Drug Class, 2017–2028

Table 9:  Europe HIV Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2017-2028

Table 10:  Europe HIV Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2017-2028

Table 11:  Europe HIV Drugs Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2017-2028

Table 12:  Germany HIV Drugs Market Revenue (USD billion) Forecast, By Drug Class, 2017–2028

Table 13:  France HIV Drugs Market Revenue (USD billion) Forecast, By Drug Class, 2017–2028

Table 14:  U.K. HIV Drugs Market Revenue (USD billion) Forecast, By Drug Class, 2017–2028

Table 15:  Italy HIV Drugs Market Revenue (USD billion) Forecast, By Drug Class, 2017–2028

Table 16:  Spain HIV Drugs Market Revenue (USD billion) Forecast, By Drug Class, 2017–2028

Table 17:  Netherlands HIV Drugs Market Revenue (USD billion) Forecast, By Drug Class, 2017–2028

Table 18:  Rest of Europe HIV Drugs Market Revenue (USD billion) Forecast, By Drug Class, 2017–2028

Table 19:  Asia Pacific HIV Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2017-2028

Table 20:  Asia Pacific HIV Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2017-2028

Table 21:  Asia Pacific HIV Drugs Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2017-2028

Table 22:  China HIV Drugs Market Revenue (USD billion) Forecast, By Drug Class, 2017–2028

Table 23:  Japan HIV Drugs Market Revenue (USD billion) Forecast, By Drug Class, 2017–2028

Table 24:  India HIV Drugs Market Revenue (USD billion) Forecast, By Drug Class, 2017–2028

Table 25:  Australia HIV Drugs Market Revenue (USD billion) Forecast, By Drug Class, 2017–2028

Table 26:  South Korea HIV Drugs Market Revenue (USD billion) Forecast, By Drug Class, 2017–2028

Table 27:  Rest of Asia Pacific HIV Drugs Market Revenue (USD billion) Forecast, By Drug Class, 2017–2028

Table 28:  Rest of the World HIV Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2017-2028

Table 29:  Rest of the World HIV Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2017-2028

Booklet
  • Jun, 2021
  • 2020
  • 2017-2019
  • 120

    CHOOSE LICENSE TYPE

  • $4850
    $5850
    $6850
    Book Now

Healthcare Clients

3M
abbvie
Amgen
Ansell
Fresenius
Galemed
Grifols
Ipsos
iqvia
Johnson
Jubilant
Lek
Pfizer
Roche
Siemens Healthineers
Styker
uniliver

Related Reports

Client Testimonials

“This report is really well done and we really appreciate it! Again, I may have questions as we dig in deeper. Thanks again for some really good work.”

- U.S.-based biotechnology company focussing on treatment of chronic pain.

“Kudos to your team. Thank you very much for your support and agility to answer our questions.”

- Europe-based provider of solutions to automate data centre operations.

“We appreciate you and your team taking out time to share the report and data file with us, and we are grateful for the flexibility provided to modify the document as per request. This does help us in our business decision making. We would be pleased to work with you again, and hope to continue our business relationship long into the future.”

- India-based manufacturer of industrial and specialty intermediates with a strong global presence.

“I want to first congratulate you on the great work done on the Medical Platforms project. Thank you so much for all your efforts.”

- One of the largest cosmetics company in the world.

“Thank you very much. I really appreciate the work your team has done. I feel very comfortable recommending your services to some of the other startups that I’m working with, and will likely establish a good long partnership with you.”

- U.S. based startup operating in the cultivated meat market.

“We received the below report on the U.S. market from you. We were very satisfied with the report.”

- UGlobal hearing aids manufacturer.

“I just finished my first pass-through of the report. Great work! Thank you!”

- U.S. based solar racking solutions provider.

“Thanks again for the great work on our last partnership. We are ramping up a new project to understand the imaging and imaging service and distribution market in the U.S.”

- World’s leading advisory firm.

“We feel positive about the results. Based on the presented results, we will do strategic review of this new information and might commission a detailed study on some of the modules included in the report after end of the year. Overall we are very satisfied and please pass on the praise to the team. Thank you for the co-operation!”

- Germany based machine construction company.

“Thank you very much for the very good report. I have another requirement on cutting tools, paper crafts and decorative items.”

- Japanese manufacturing company of stationery products.

“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”

- One of the Leading Food Companies in Germany

“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”

- Intuitive Surgical

“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”

- Major Food Company in Japan

“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”

- Ziering Medical

“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”

- Major Manufacturer of Precision Machine Parts in India

“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”

- Hewlett-Packard

“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”

- Global Management Consulting Firm

“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”

- UK-based Start-up in the Medical Devices Sector

“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”

- One of the Largest Companies in the Defence Industry
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . Privacy.
X